Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2025/07/091845
CTRI/2025/07/091845
Not yet recruiting
Not Applicable

Study of incidence, resistance patterns, efficacy of ceftazidime-avibactam and aztreonam in critically ill patients with carbapenem resistant enterobacterales (CRE) infection in a tertiary care setup- A prospective observational study

BLK MAX SUPERSPECIALITY OSPITAL1 site in 1 country84 target enrollmentStarted: August 8, 2025Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Not Applicable
Status
Not yet recruiting
Sponsor
BLK MAX SUPERSPECIALITY OSPITAL
Enrollment
84
Locations
1
Primary Endpoint
TO FIND THE INCIDENCE OF CRE INFECTION AND 28 DAY MORTALITY IN ADULT PATIENTS ADMITTED IN MICU
OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Overview

Brief Summary

study of incidence, resistance patters, efficacy of ceftazidime-avibactam and aztreonam in critically ill patients with carbap[enem resistant enterobacterales infection in tertiary care setup-a prospective observational study

Study Design

Study Type
Observational

Eligibility Criteria

Ages
18.00 Year(s) to 99.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • •PREGNANT PATIENTS PATIENT UNLIKELY TO SURVIVE BEYOND 48 HOUR CANCER DIAGNOSIS IMMUNOSUPPRESSIVE/ANTI CANCER THERAPY.

Outcomes

Primary Outcomes

TO FIND THE INCIDENCE OF CRE INFECTION AND 28 DAY MORTALITY IN ADULT PATIENTS ADMITTED IN MICU

Time Frame: TO FIND THE INCIDENCE OF CRE INFECTION AND 28 DAY MORTALITY IN ADULT PATIENTS ADMITTED IN MICU

Secondary Outcomes

  • TO STUDY THE TIME TO MICROBIOLOGICAL AND CLINICAL CURE IN ADULT PATIENTS WITH CRE IN ICU
  • TO STUDY THE RISK FACTORS, ANTIBIOTIC SUSCEPTIBILITY AND RESISTANCE PATTERN (MIC VALUE AND BREAK POINTS) IN ADULT PATIENTS WITH CRE IN ICU
  • TO STUDY THE FOLLOWING(synergy between CAZ-AVI+ATM)

Investigators

Sponsor
BLK MAX SUPERSPECIALITY OSPITAL
Sponsor Class
Private hospital/clinic
Responsible Party
Principal Investigator
Principal Investigator

priyanka sagar

BLK MAX SUPERSPECIALITY HOSPITAL

Study Sites (1)

Loading locations...

Similar Trials

Not yet recruiting
Phase 4
Impact of Rapid Diagnostics using a FilmArray Test and Early Targeted Treatment with Ceftazidime-Avibactam for Management of Severe Infections: A Comparative Study Against Standard Care
CTRI/2024/04/066197ADVANCE ID5,900
Not yet recruiting
Phase 1
Comparing the efficacy of two antibiotic groups for gram negative sepsis in intensive care unit
CTRI/2024/04/065863Trishita Saha80
Not yet recruiting
Not Applicable
Effect of Ceftazidime-Avibactam on Carbapenemase-Producing Klebsiella Pneumoniae
NCT07369518Sohag University100
Recruiting
Phase 2/3
Effect of Ceftazidime Avibactam (drug) Versus Meropenem (drug) in Patients of ACLF (Liver Disease).
CTRI/2025/02/080203Institute of Liver and Biliary Sciences150
Not yet recruiting
Phase 4
Comparing the efficacy of single dose Azithromycin vs multiple dose Cefuroxime in addition to Ceftriaxone to Prevent post-surgery infection in women undergoing cessarean section
CTRI/2024/12/077949All India Institute of Medical Sciences178